[Malignant lymphoma: magnetic resonance tomography findings in residual supradiaphragmatic space-occupying lesions]

Rofo. 1999 Sep;171(3):192-9. doi: 10.1055/s-1999-247.
[Article in German]

Abstract

Purpose: Evaluation of MR imaging in patients with Hodgkin's lymphoma and high grade non-Hodgkin's-lymphoma and mediastinal residual mass after first line chemotherapy.

Materials and methods: MR imaging (1.5 T) was performed in 36 patients (Hodgkin's lymphoma n = 26, NHL n = 10) after first line chemotherapy). Twenty patients had inactive residual mass, 16 patients had residual lymphoproliferative lesions. T1- and T2-weighted spin echo images were visually analysed by a score index (range 1-5) as well as quantification of enhancement by signal-intensity-ratios SImax/SIplain).

Results: For the differentiation between residual lymphoproliferative activity and inactive residual mass, the highest accuracy was obtained for the signal intensity of residual mass on T2-w-SE compared to pectoralis muscle (94% sensitivity, 80% specificity, likelihood ratios: 4.0 [LR+]; 0.3 [LR-]). The cut-off value of the SI ratio was calculated retrospectively at 1.96 (p > 0.05).

Conclusions: Differentiation between inactive (fibrotic) and lymphoproliferative (active) residual mediastinal mass is possible by MR imaging using as parameter the size reduction after therapy and the signal intensity on T2-w-SE in comparison to pectoralis muscle. Thus study suggests an additional value using the SI ratio for the differentiation.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cyclophosphamide / administration & dosage
  • Doxorubicin / administration & dosage
  • Female
  • Hodgkin Disease / diagnosis*
  • Hodgkin Disease / drug therapy
  • Hodgkin Disease / pathology
  • Humans
  • Lymph Nodes / pathology
  • Lymphoma, Non-Hodgkin / diagnosis*
  • Lymphoma, Non-Hodgkin / drug therapy
  • Lymphoma, Non-Hodgkin / pathology
  • Magnetic Resonance Imaging*
  • Male
  • Mediastinal Neoplasms / diagnosis*
  • Mediastinal Neoplasms / drug therapy
  • Mediastinal Neoplasms / pathology
  • Mediastinum / pathology
  • Middle Aged
  • Neoplasm Staging
  • Neoplasm, Residual / diagnosis*
  • Neoplasm, Residual / drug therapy
  • Neoplasm, Residual / pathology
  • Prednisone / administration & dosage
  • Prognosis
  • Sensitivity and Specificity
  • Vincristine / administration & dosage

Substances

  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol